Rocket Pharmaceuticals (RCKT) EBT (2016 - 2025)
Historic EBT for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$52.0 million.
- Rocket Pharmaceuticals' EBT rose 2414.68% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 745.13%. This contributed to the annual value of -$266.8 million for FY2024, which is 412.81% down from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' EBT is -$52.0 million, which was up 2414.68% from -$71.1 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' EBT registered a high of -$33.8 million during Q2 2021, and its lowest value of -$71.9 million during Q2 2024.
- For the 5-year period, Rocket Pharmaceuticals' EBT averaged around -$57.9 million, with its median value being -$61.6 million (2024).
- Examining YoY changes over the last 5 years, Rocket Pharmaceuticals' EBT showed a top increase of 2753.09% in 2021 and a maximum decrease of 7122.35% in 2021.
- Rocket Pharmaceuticals' EBT (Quarter) stood at -$43.9 million in 2021, then crashed by 55.43% to -$68.3 million in 2022, then increased by 7.86% to -$62.9 million in 2023, then increased by 2.2% to -$61.6 million in 2024, then rose by 15.5% to -$52.0 million in 2025.
- Its last three reported values are -$52.0 million in Q3 2025, -$71.1 million for Q2 2025, and -$63.5 million during Q1 2025.